GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
LEXICON PHARMACEUTCL (LXRX) [hlAlert]

Rating:
Buy LXRX
up 16.29 %

LEXICON PHARMACEUTCL (LXRX) rated Buy with price target $3 by Needham

Posted on: Friday,  May 27, 2011  8:25 AM ET by Needham

Needham rated Buy LEXICON PHARMACEUTCL (NASDAQ: LXRX) on 05/27/2011, when the stock price was $10.43. Since
then, LEXICON PHARMACEUTCL has gained 16.30% as of 01/04/2016's recent price of $12.13.
If you would have followed this Needham's recommendation on LXRX, you would have gained 16.29% of your investment in 1683 days.

Lexicon Pharmaceuticals, Inc. (Lexicon), is a biopharmaceutical company focused on discovering and developing treatments for human disease. The Company uses its proprietary gene knockout technology to identify and develop new drugs. In its Genome5000 program, Lexicon is utilizing its knowledge of the function of nearly 5,000 genes to identify a portfolio of drug targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a diverse pipeline of drug targets behind its clinical programs with many compounds and antibodies in preclinical research. Lexicon is conducting clinical trials for four drug candidates, with its most advanced program in Phase II clinical trials.

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/27/2011 8:25 AM Buy
None
10.43 21.00
as of 12/30/2011
1 Week up  11.20 %
1 Month up  10.25 %
3 Months up  40.21 %
1 YTD down  -13.42 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy